Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Smith & Nephew plc (SNN) Price & Performance

YieldMax AMZN Option Income Strategy ETF
Smith & Nephew plc

Price performance

Price movement over the last 24 hours

Key statistics

YieldMax AMZN Option Income Strategy ETF vs Smith & Nephew plc — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $10.74, while Smith & Nephew plc trades at $30.7 (market cap $12.69B). The key difference: Smith & Nephew plc pays a 2.55% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and Smith & Nephew plc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.

AMZYSNN
Sector
Income / Options OverlayHealth
52-Week High
$16.61$38.70
52-Week Low
$10.26$28.73
Market Cap
$12.69B
Enterprise Value
$15.46B
Dividend Yield
2.55%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax AMZN Option Income Strategy ETF

AMZY trades at $10.78 with no significant daily movement, showing neutral technical signals overall. The ETF maintains a consistent weekly dividend distribution strategy, though recent analyst commentary highlights concerns about NAV erosion despite high yields. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance levels cluster tightly around $10-11.

The outlook remains cautious as the synthetic option strategy delivers high income but exposes investors to amplified downside risk. While weekly distributions provide income appeal, total returns have lagged the underlying Amazon stock, creating sustainability concerns for long-term investors seeking both income and capital appreciation.

Smith & Nephew plc

Smith & Nephew (SNN) trades at $30.70, up 0.99% with a bullish technical signal supported by moving averages. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B (2024-2025) and net income margin expanding to 10.14%. Recent developments include new medical guidance publications and robotics platform advancements, while analyst consensus remains cautious with 68% hold ratings.

SNN presents a mixed outlook with strong profitability metrics and positive cash flow trends offset by recent earnings misses and conservative analyst sentiment. Investment opportunity lies in the company's medical technology innovations and margin expansion, though risks include competitive pressures and execution challenges in meeting growth targets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About YieldMax AMZN Option Income Strategy ETF

AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.

Read more on AMZY

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN